Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: Open‐label, noncomparative, multicenter, long‐term follow‐up study

Abstract

Adjunctive LEV (range 1,000-4,000 mg/day) demonstrated efficacy as a long-term treatment for primary generalized seizures in children, adolescents, and adults with IGE, and was well tolerated.